This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, K. C. Articles by Ross, B. D. Search for Related Content PubMed PubMed Citation Articles by Lee, K. C. Articles by Ross, B. D.

Dynamic Imaging of Emerging Resistance during Cancer Therapy

Departments of ¹ Biological Chemistry, ² Radiology, ³ Biostatistics, and ⁴ Radiation Oncology and ⁵ Center for Molecular Imaging, University of Michigan Medical School; ⁶ MIR Preclinical Services, Ann Arbor, Michigan; and ⁷ Roswell Park Cancer Institute, Buffalo, New York

Requests for reprints: Brian D. Ross, University of Michigan Medical School, Kresge II, 200 Zina Pitcher Place, Ann Arbor, MI 48109. Phone: 734-763-2099; Fax: 734-763-5447; E-mail: bdross{at}umich.edu.

One of the greatest challenges in developing therapeutic regimens is the inability to rapidly and objectively assess tumor response due to treatment. Moreover, tumor response to therapeutic intervention in many cases is transient, and progressive alterations within the tumor may mask the effectiveness of an initially successful therapy. The ability to detect these changes as they occur would allow timely initiation of alternative approaches, maximizing therapeutic outcome. We investigated the ability of diffusion magnetic resonance imaging (MRI) to provide a sensitive measure of tumor response throughout the course of treatment, possibly identifying changes in sensitivity to the therapy. Orthotopic 9L gliomas were subjected to two separate therapeutic regimens, with one group receiving a single 5-day cycle (1) of low-dose 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and a second group receiving two cycles at the same dose, bisected with 2 days of rest (2). Apparent diffusion coefficient maps were acquired before and throughout treatment to observe changes in water mobility, and these observations were correlated to standard measures of therapeutic response and outcome. Our results showed that diffusion MRI was indeed able to detect the emergence of a drug-resistant tumor subpopulation subsequent to an initially successful cycle of BCNU therapy, leading to minimal gains from a second cycle. These diffusion MRI findings were highly correlated with tumor growth delay, animal survival, and ex vivo growth inhibition assays showing emerging resistance in excised tumors. Overall, this study highlights the ability of diffusion MRI to provide sensitive dynamic assessment of therapy-induced response, allowing early opportunities for optimization of therapeutic protocols. (Cancer Res 2006; 66(9): 4687-92)

This article has been cited by other articles:

				E. R. Gerstner, P.-J. Chen, P. Y. Wen, R. K. Jain, T. T. Batchelor, and G. Sorensen Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib Neuro Oncology, January 22, 2010; (2010): nop051v1 - nop051. [Abstract] [Full Text] [PDF]

				D. A. Hamstra, C. J. Galban, C. R. Meyer, T. D. Johnson, P. C. Sundgren, C. Tsien, T. S. Lawrence, L. Junck, D. J. Ross, A. Rehemtulla, et al. Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival J. Clin. Oncol., July 10, 2008; 26(20): 3387 - 3394. [Abstract] [Full Text] [PDF]

				D. A. Hamstra, A. Rehemtulla, and B. D. Ross Diffusion Magnetic Resonance Imaging: A Biomarker for Treatment Response in Oncology J. Clin. Oncol., September 10, 2007; 25(26): 4104 - 4109. [Abstract] [Full Text] [PDF]

				P. McConville, D. Hambardzumyan, J. B. Moody, W. R. Leopold, A. R. Kreger, M. J. Woolliscroft, A. Rehemtulla, B. D. Ross, and E. C. Holland Magnetic Resonance Imaging Determination of Tumor Grade and Early Response to Temozolomide in a Genetically Engineered Mouse Model of Glioma Clin. Cancer Res., May 15, 2007; 13(10): 2897 - 2904. [Abstract] [Full Text] [PDF]

				K. C. Lee, S. Sud, C. R. Meyer, B. A. Moffat, T. L. Chenevert, A. Rehemtulla, K. J. Pienta, and B. D. Ross An Imaging Biomarker of Early Treatment Response in Prostate Cancer that Has Metastasized to the Bone Cancer Res., April 15, 2007; 67(8): 3524 - 3528. [Abstract] [Full Text] [PDF]

				K. C. Lee, D. A. Hamstra, M. S. Bhojani, A. P. Khan, B. D. Ross, and A. Rehemtulla Noninvasive Molecular Imaging Sheds Light on the Synergy between 5-Fluorouracil and TRAIL/Apo2L for Cancer Therapy Clin. Cancer Res., March 15, 2007; 13(6): 1839 - 1846. [Abstract] [Full Text] [PDF]

				K. C. Lee, B. A. Moffat, A. F. Schott, R. Layman, S. Ellingworth, R. Juliar, A. P. Khan, M. Helvie, C. R. Meyer, T. L. Chenevert, et al. Prospective Early Response Imaging Biomarker for Neoadjuvant Breast Cancer Chemotherapy Clin. Cancer Res., January 15, 2007; 13(2): 443 - 450. [Abstract] [Full Text] [PDF]